Endobronchial treatment and follow up of malignant central airway obstruction


Kaid Darwiche
Ruhrländklinik
Essen
Germany
I have no, real or perceived, direct or indirect conflicts of interest that relate to this presentation.

I have the following, real or perceived direct or indirect conflicts of interest that relate to this presentation:

<table>
<thead>
<tr>
<th>Affiliation / financial interest</th>
<th>Nature of conflict / commercial company name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobacco-industry and tobacco corporate affiliate related conflict of interest</td>
<td></td>
</tr>
<tr>
<td>Grants/research support (to myself, my institution or department):</td>
<td>Bess/Leufen, PulmonX, Novartis</td>
</tr>
<tr>
<td>Honoraria or consultation fees:</td>
<td>PulmonX, Boehringer Ingelheim</td>
</tr>
<tr>
<td>Participation in a company sponsored bureau:</td>
<td></td>
</tr>
<tr>
<td>Stock shareholder:</td>
<td></td>
</tr>
<tr>
<td>Spouse/partner:</td>
<td></td>
</tr>
<tr>
<td>Other support or other potential conflict of interest:</td>
<td></td>
</tr>
</tbody>
</table>

This event is accredited for CME credits by EBAP and speakers are required to disclose their potential conflict of interest going back 3 years prior to this presentation. The intent of this disclosure is not to prevent a speaker with a conflict of interest (any significant financial relationship a speaker has with manufacturers or providers of any commercial products or services relevant to the talk) from making a presentation, but rather to provide listeners with information on which they can make their own judgment. It remains for audience members to determine whether the speaker’s interests or relationships may influence the presentation. Drug or device advertisement is strictly forbidden.
Central Airway Obstruction

- Indications for Intervention
- Methods
- Follow up
- Future Perspectives
Lung Carcinoma

- 5-Year survival rate <20%
- Curative resection <30%
- 30% present with central airway obstruction
- Symptoms
  - Dyspnea
  - Infections
  - Hemoptysis

Ernst A, et al; Am J Respir Crit Care Med 2004
Central Airway Obstruction
Central Airway Obstruction

- n=53, 58y, 29m/24f
- Prospective study
- 24 malignant, 29 benign Stenosis (many post LuTx)
- 40 Stents (19 SEMS, 10 Silicon, 11, Hybrid)
- Balloon-Dilatation, HF, APC, Laser, Debridement
- Lung function, SOBQ and SF-36 before and 6-8 weeks after Intervention

Mahmood K, Wahidi, MM et al. Respiration 2015
Central Airway Obstruction

Significant Improvement
- Lung Function
- Dyspnea (SOBQ 55.8 to 37.9)
- Quality of Life

Successful intervention of malignant Stenosis
- Improvement of Survival

Mahmood K, Wahidi, MM et al. Respiration 2015
Central Airway Obstruction

Indication of Intervention?

• Symptomatic stenosis?
• Secretion retention?
• Viable lung tissue?
• Oncologic Concept?
Central Airway Obstruction

Immediate Results after Nd:YAG Laser-Resection
(Site/Number of Treatments/Successful Disobliteration)

- 502 (97%)
- 560 (92%)
- 286 (66%)
- 315 (72%)
- 382 (49%)
- 489 (90%)
- 131 (60%)
- 225 (77%)
- 708 (95%)

Endoscopic Treatment of Malignant Airway Obstructions in 2008 Patients
Malignant Airway Stenosis

Treatment Options in CAO

**Immediate Effect**
- Mechanical Techniques
  - Mechanical Debulking
  - „Coring out“
  - Cryorecanalisation
  - Stent
  - Microdebrider
- Thermal Techniques
  - Argonplasma-Coagulation
  - Laser
  - Electrocautery (Knife/Snare)

**Delayed Effect**
- Cryotherapy
- Brachytherapy
- Photodynamic Therapy
„Coring out“
“Coring out”

- Rapid desobliteration
- Immediate symptom relief
- Only suitable for exophytic tumor growth
- Risk of bleeding
- Perforation
Cryotherapy/Cryorecanalisation

- Re-opening success rate of 91%
- Mild/moderate bleeding 12%
- Improvement of dyspnea, cough, lung function and QoL

Asimakopoulos, G et al. Chest 2005
Maiwand MO et al, Technol Cancer Res Treat 2004
Cryo-Recanalisation
What about Laser light?

Macha et al, Chest 1994
Brutinel et al, Chest 1987
Cavliere et al, Chest 1996
Noppen et al, Ann Oncol 2002

Laser is cool!
Endobronchial Laser Resection

- 75 Pat. with and 75 Pat. without laser resection
- matched pair analysis
- Successful laser resection improved OS by 4 month

Macha et al. Chest 1994
Endobronchial Laser Resection

- limited haemostatic properties
- financial resources
- legal requirements
- safety issues (wavelength-specific eyewear, etc)
- very precise instrument
- benign cicatricial stenosis
- diode laser > Nd-YAG-Laser
Stents

- 14 Pat. with CAO
  - 10 Tumor compression, 4 Post-therapeutic scar/malacia
  - 9 Trachea, 5 Main stem bronchus
- Silicone-Stents were placed in all patients
- Complications n=3
  - Granulation tissue, Tumor growth, Migration
- FEV1 improved from 1.27 to 1.72 l

Vergnon JM et al. Chest 1995
Stents

- 60 Pat. with CAO
  - 50 Lung carcinoma, 3 Esophageal carcinoma, 7 metastases
  - 5 Trachea, 50 Main stem/Intermediate Br., 7 Lobar Br.

- Successful re-opening in all patients
- Symptom relief in all patients
- Mean Survival 160 days
- Complications 23%:
  - Mucus plugging 8%
  - Granulation tissue 5%
  - Tumor ingrowth 5%
  - Stent migration 5%
- FEV1 improved from 1.45 to 1.78 l (p = 0.003)

Breitenbücher A et al. Respiration 2008
Follow-Up Bronchoscopy after Intervention

- After Stent-Placement
  - High rate of complications
- Slow-growing lung cancer with CAO
  - Progress can be detected earlier
- Definite endoscopic treatment
- CAO after curative radiotherapy
  - Risk of cicatricial stenosis
Photodynamic Therapy

- Injektion of a sensitizer
- Activation with Laser
- Cytotoxic reaction
- Selective destruction of tumor cells

White light  AF  PDT  24h
PDT with Photofrin Response Rates in Early Lung Cancer

110 patients, 123 lesions

< 0.5 cm  CR 95 %
< 1 cm     CR 88 %
< 2 cm     CR 45 %
> 2 cm     CR 43 %

≥1.5 cm + Brachytherapie     CR 84%

Furuse K et al. J Clin Oncol 1993
Sutedja TG, J Bronchol 1994
An open-label phase IIb study to evaluate the safety, tolerability and efficacy of Fotolon® as a photosensitising agent for the local treatment of airway-obstructing non small cell lung cancer (NSCLC) with photodynamic therapy (PDT)

**Study Code:** AC_PDT_Lung_01

**EudraCT number:** 2013-001876-39

**Previous version Number:** Final V1.0

**Final version date:** 2014-03-17

Last patient included two weeks before
Cryobiopsy for genomic profiling

Biodegradable Stents

after 3 months
Conclusion

• Interventional Bronchoscopy improve lung function, dyspnea and Quality of Life in patients with malignant CAO

• This treatment should be part of standard palliative strategy for patients with CAO

• Follow-up bronchoscopy is recommended in patients after stent placement and if relaps/progress of CAO is probable
Thank you for your attention